Finding good prospects is like hunting gold in the fast-paced world of investing. Three stocks stand out in this hunt, all under $10, with significant growth potential. These companies operate in a variety of industries, including technology and healthcare. They offer a unique opportunity to profit from rapid revenue growth, strong financial stability and well-thought-out development strategies. With a robust organic revenue increase in the first quarter and a solid focus on the hyaluronic acid (HA) busines ...

Chase Knickerbocker - Craig-Hallum Robbie Marcus - JPMorgan Chase & Co. Caitlin Cronin - Canaccord Genuity Thank you, Andrea, and good morning, everyone, and thanks for joining us. It is my pleasure to welcome you to the Bioventus 2024 first-quarter earnings conference call. With me this morning are Rob Claypoole, President and CEO; and Mark Singleton, Senior Vice President and CFO. Rob will begin his remarks with an update on our 2024 priorities in our business. Mark will provide detail of our first-quarte ...

Exhibit 99.1 DURHAM, NC – May 7, 2024 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 30, 2024. First Quarter 2024 Financial Results: *See below under "Use of Non-GAAP Financial Measures" for more details. The following table represents net sales by geographic region, and by business, for the three months ended March 30, 2024 and April 1, 2023: (a) Sales from the SonicOne produ ...

DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 a ...

Financial Performance - Q4 2023 - Revenue increased by 8% to $135 million compared to the prior year quarter[26] - Pain Treatments revenue increased 23% compared to prior year[27] - Surgical Solutions revenue grew 12%[27] - Adjusted EBITDA increased by $5 million to $22 million compared to the prior year quarter[26] - Adjusted gross margin increased 20 basis points to 71.4%[30, 31] Financial Position - Debt outstanding is $395 million[35] - Cash balance at the end of the quarter is $37 million[50] 2024 Financial Guidance - Expect net sales to be in the range of $520 million to $535 million[51] - Expect adjusted EBITDA to be in the range of $89 million to $94 million[37] Strategic Initiatives - Accelerating revenue growth, especially in Ultrasonics with double-digit growth expected[7] - Prioritizing funding initiatives and re-allocating resources to maximize return[7] - Improving operational efficiency and reducing expenses related to integrations and debt restructuring[18] - Organic revenue growth increased 14% compared to the prior year quarter when adjusting for the divestiture of Wound Business[21]

Bioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Conference Call March 12, 2024 8:30 AM ET Company Participants Dave Crawford - Vice President, Investor Relations Rob Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Caitlin Cronin d - Canaccord Genuity Operator Good day, and welcome to the Bioventus Inc. Fourth Quarter 2023 Earnings Conference Call. [Operator Instruct ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------|-------|--------------------------|-------|--------------------------------------|-------|-------|----------------|-------|------------------------------|-------|-----------------------------------|-------|------------------------------------| | Year Ended December 31, 2022 \nReported GAAP measure | $ | Gross Profit \n331,080 | $ | Operating Expenses (a) ...

SECURITIES AND EXCHANGE COMMISSION ________________ ________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-37844 (Exact Name of Registrant as Specified in Its Charter) | --- | |-----------------------------| | | | | | Accelera ...

gilaxia Bioventus Inc. (NASDAQ:BVS) has emerged as an impressive turnaround story moving forward from its troubled post-IPO period where the company faced a major setback from its failed acquisition of "CartiHeal". The stock has more than doubled over the past year with the leader in therapeutic injections for osteoarthritis capturing a new round of operating momentum in recent quarters. Indeed, we last covered BVS back in October highlighting the improving outlook which was ultimately confirmed by a strong ...

DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has entered into an Amendment No. 5 (the "Amendment") to the Credit and Guaranty Agreement, between the Company, Wells Fargo Bank, National Association as Administrative Agent and Collateral Agent, and the Lenders from time to time party thereto, dated as of December 6, 2019 and as amended on August 29, 2021, October 29, 2021, ...